Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,392.00
Bid: 12,376.00
Ask: 12,380.00
Change: -74.00 (-0.59%)
Spread: 4.00 (0.032%)
Open: 12,466.00
High: 12,512.00
Low: 12,330.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Czechs may follow Hungary in using vaccines not registered in EU - PM

Fri, 05th Feb 2021 15:34

(Adds details,)

BUDAPEST, Feb 5 (Reuters) - The Czech Republic may consider
using vaccines not yet registered in the EU to speed up
inoculations, Prime Minister Andrej Babis said on Friday, on a
trip to Hungary which has given emergency approval to Russian
and Chinese vaccines.

He said he had also spoken about the issue with German
officials, including Chancellor Angela Merkel, who he said
wanted Russian or Chinese vaccines to be given European
approval.

European Union countries' governments are facing a reckoning
over vaccination programmes that have lagged far behind the
United States and former EU member Britain.

Hungary so far is the only EU member to have given emergency
use approval to Chinese and Russian vaccines. Other EU countries
have followed the European regulator EMA, which has so far
approved only three vaccines from Western companies.

"I have spoken about the Russian vaccine, and about the
Chinese vaccine, with Chancellor Merkel, and the chancellor as
well as the Bavarian prime minister are unambiguously calling
for this vaccine to be approved by the European Medicines Agency
(EMA)," Babis said after meeting Hungarian Prime Minister Viktor
Orban.

"Now of course the issue is whether the producer asks for
the approval or not, and we of course want to consider, if we
get hold of the vaccine, to go the similar way as Hungary did
because time is of essence."

Babis did not respond to a request for further comment.
Prior to his trip to Budapest, he said he aimed to discuss
Russia's Sputnik V vaccine with Orban.

Czech authorities had until Friday insisted on EMA clearance
for any vaccine to be used in the country.

Peer-reviewed late-stage trial results of Sputnik V
published in The Lancet international medical journal this week
showed it was almost 92% effective in fighting COVID-19.

Russia has shared data from its Phase III trial with
regulators in several countries and has begun the process of
submitting it to the EMA for approval in the European Union.

China has produced two vaccines, from Sinopharm and Sinovac,
and has been exporting millions of doses of each of them around
the world, mainly to developing countries.

The Czech Republic has suffered one of the world's highest
infection and death rates, with 16,976 deaths in the population
of 10.7 million.

It has so far administered 327,759 vaccine doses from
Pfizer/BioNTech and Moderna, mostly to citizens over the age of
80 and health workers, and expects the first shipment of
AstraZeneca vaccines on Saturday.
(Reporting by Gergely Szakacs in Budapest, Jan Lopatka and
Robert Muller in Prague)

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.